RO5545965

DRUG5 trials

Sponsors

Hoffmann-La Roche

Conditions

Healthy VolunteerSchizophrenia

Phase 1

A Study of Safety, Pharmacokinetics (Including Food Effect) And Pharmacodynamics of RO5545965 in Healthy Volunteers

CompletedNCT01711801

Hoffmann-La RocheHealthy Volunteer

Start: 2012-10-31End: 2013-03-31Updated: 2016-11-02

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 in Healthy Volunteers

CompletedNCT01864226

Hoffmann-La RocheHealthy Volunteer

Start: 2013-06-30End: 2014-01-31Updated: 2016-11-02

A PET Study With RO5545965 in Healthy Male Volunteers

CompletedNCT01923025

Hoffmann-La RocheSchizophrenia

Start: 2013-08-31End: 2013-11-30Updated: 2016-11-02

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

CompletedNCT02019329

Hoffmann-La RocheSchizophrenia

Start: 2014-01-31End: 2014-08-31Updated: 2016-11-02

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

CompletedNCT02824055

Hoffmann-La RocheSchizophrenia

Start: 2016-06-27End: 2017-04-24Updated: 2017-06-07

Related Papers

Exploratory analysis of the relationship between striatal connectivity and apathy during phosphodiesterase 10 inhibition in schizophrenia: findings from a randomized crossover trial

BMC Medicine2025-03-282 citations

Deep Learning-Based Human Activity Recognition for Continuous Activity and Gesture Monitoring for Schizophrenia Patients With Negative Symptoms.

2020-09-1611 citations